Structure Therapeutics Inc. - American Depositary Shares (GPCR)
21.76
+3.23 (17.43%)
NASDAQ · Last Trade: Apr 18th, 4:34 PM EDT
Detailed Quote
Previous Close
18.53
Open
21.50
Bid
20.00
Ask
21.50
Day's Range
19.74 - 24.17
52 Week Range
13.22 - 62.74
Volume
5,812,175
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,116,058
Chart
About Structure Therapeutics Inc. - American Depositary Shares (GPCR)
Structure Therapeutics Inc. is a biotechnology company that focuses on the discovery and development of innovative therapies targeting G protein-coupled receptors (GPCRs), which are essential in mediating various physiological processes and diseases. By leveraging advanced structural biology and computational techniques, the company aims to design small molecule treatments for a range of conditions, including metabolic disorders and neurodegenerative diseases. Through its research efforts, Structure Therapeutics strives to create effective and targeted therapeutics that can improve patient outcomes and contribute to advancements in personalized medicine. Read More
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK.
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced multiple upcoming posters at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 3-6, 2024 in San Antonio, TX.
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.
